EMERAMED LIMITED

Emeramed Limited is a biotechnology firm focused on developing Emeramide, a novel lipophilic compound that can cross the blood-brain barrier and act as both a powerful antioxidant and a metal chelator. By binding free iron, mercury, lead and other heavy metals, Emeramide helps to neutralise free radicals and restore normal mitochondrial function, offering a potential route to improved overall health.

The company's lead product is currently being evaluated for a range of conditions. A Phase 2a clinical trial in chronic obstructive pulmonary disease (COPD) completed in summer 2018 demonstrated that Emeramide is safe with no adverse effects, and pre-clinical studies are underway for additional indications. Emeramed is also pursuing regulatory approval with the US FDA and actively combats the sale of counterfeit versions of the compound, working closely with authorities to protect patients.

Through rigorous research and a commitment to safety, Emeramed aims to address the underlying oxidative stress that contributes to many diseases, positioning Emeramide as a versatile therapeutic tool for both heavy-metal detoxification and antioxidant support.